FDA’s Off-Label Dissemination Guidance Opens “Loophole” – Rep. Waxman
Executive Summary
Rep. Henry Waxman, D-Calif., made another move in his fight against off-label drug promotion Nov. 30, releasing an internal FDA 1draft guidance on "good reprint practices" and sending a strongly worded 2letter to Commissioner Andrew von Eschenbach
You may also be interested in...
Good Reprint Practices: FDA’s Draft Guidance Aims For Middle Ground
A newly released FDA draft guidance detailing a roadmap for acceptable dissemination of information on off-label drug use implies that companies need to garner enough data for a new drug application before distributing content
Good Reprint Practices: FDA’s Draft Guidance Aims For Middle Ground
A newly released FDA draft guidance detailing a roadmap for acceptable dissemination of information on off-label drug use implies that companies need to garner enough data for a new drug application before distributing content
Off-Label Dissemination May Be Clarified – Indirectly – By FDAAA Regs
Issues surrounding off-label dissemination may be clarified through regulations required by the FDA Amendments Act of 2007